Capricor Therapeutics (CAPR) announced the appointment of Philip Gotwals, Ph.D., to its Board of Directors, effective immediately. Dr. Gotwals, most recently the Global Head, Vice President of Business Development and Licensing at Novartis Institutes (NVS) for Biomedical Research, brings his strategic vision for research, innovation for drug development and valuable industry experience to the Company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CAPR:
- Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors
- Capricor Therapeutics announces appointment of Auwaerter to board of directors
- Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors
- Capricor Therapeutics announces 24-month results from HOPE-2 study
- Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy